volume 2, issue 8, PS517 2007
DOI: 10.1097/01.jto.0000283531.34858.74
View full text
|
|
Share

Abstract: Background: The prognosis of lung cancer is still poor, since there are few early detection tools available yet. So, it is important to identify more efficient and clinically applicable biomarkers associated with the prognosis in as earlier stages as possible. Method: In this study, we firstly observed the expression profile of CD63 in 33 cases of non-small cell lung cancers (NSCLC) using realtime quantitative RT-PCR. To explore the potential of this molecule as a prognostic biomarker for lung cancer subtypes,…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals